Literature DB >> 7000629

Renin-angiotensin-aldosterone system in cirrhosis.

S P Wilkinson, R Williams.   

Abstract

According to traditional concepts, ascites formation and portal hypertension in cirrhosis lead to a deficit in the 'effective' extracellular fluid (ECF) and blood volumes respectively. The renin-angiotensin-aldosterone (RAA) system is thus stimulated and the kidneys retain fluid as a homeostatic mechanism to restore the ECF and blood volumes. Recent studies, however, show that approximately two-thirds of patients with ascites do not have a stimulated RAA system and in those without clinical evidence of fluid retention the RAA system is actually suppressed. These findings are incompatible with the concepts of reduced effective ECF and blood volumes. Despite the fact that most patients retaining sodim and accumulating ascites have a normal plasma aldosterone concentration, other evidence strongly suggests a dominant role for aldosterone in the regulation of renal sodium excretion. There might therefore be an increased renal tubular sensitivity to aldosterone in cirrhosis. For the one-third of patients with ascites who do have a stimulated RAA system this may well be a response to reduced effective ECF and/or blood volumes in accord with traditional concepts.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7000629      PMCID: PMC1419648          DOI: 10.1136/gut.21.6.545

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  54 in total

1.  Hyperaldo-steronism in liver disease. The treatment of refractory ascites by adrenalectomy and by the administration of spirolactones.

Authors:  K S HENLEY; D H STREETEN; H M POLLARD
Journal:  Gastroenterology       Date:  1960-05       Impact factor: 22.682

2.  Circulatory changes in chronic liver disease.

Authors:  J F MURRAY; A M DAWSON; S SHERLOCK
Journal:  Am J Med       Date:  1958-03       Impact factor: 4.965

3.  Renal retention of sodium in cirrhosis and fulminant hepatic failure.

Authors:  S P Wilkinson; H Moodie; A Alam; R Williams
Journal:  Postgrad Med J       Date:  1975-08       Impact factor: 2.401

4.  Plasma renin level in hepatic cirrhosis. Relaton to functional renal failure.

Authors:  E T Schroeder; R H Eich; H Smulyan; A B Gould; G J Gabuzda
Journal:  Am J Med       Date:  1970-08       Impact factor: 4.965

5.  Changes in plasma renin activity in cirrhosis: a reappraisal based on studies in 67 patients and "low-renin" cirrhosis.

Authors:  S P Wilkinson; I K Smith; R Williams
Journal:  Hypertension       Date:  1979 Mar-Apr       Impact factor: 10.190

6.  Compartmentalization of ascites and edema in patients with hepatic cirrhosis.

Authors:  L Shear; S Ching; G J Gabuzda
Journal:  N Engl J Med       Date:  1970-06-18       Impact factor: 91.245

7.  Pressure-dependent heterogeneity of renal cortical blood flow in dogs.

Authors:  J L McNay; Y Abe
Journal:  Circ Res       Date:  1970-10       Impact factor: 17.367

8.  Renal function changes in cirrhosis of the liver. A prospective study.

Authors:  E L Klingler; C A Vaamonde; L S Vaamonde; R G Lancestremere; H J Morosi; E Frisch; S Papper
Journal:  Arch Intern Med       Date:  1970-06

9.  Secretion and turnover of aldosterone in various pathological states.

Authors:  P Vecsei; G Düsterdieck; J Jahnecke; D Lommer; H P Wolff
Journal:  Clin Sci       Date:  1969-04       Impact factor: 6.124

10.  [Study of inulin and PAH clearances, cardiac output, exchangeable Na and K and extracellular fluids during the development of liver cirrhosis].

Authors:  H D Traverso; C Raynaud; P Blanchon; A Roberti; P Vesin; R Viguie; C Kellershohn
Journal:  Rev Int Hepatol       Date:  1966
View more
  17 in total

Review 1.  The hepatorenal syndrome.

Authors:  L Dagher; K Moore
Journal:  Gut       Date:  2001-11       Impact factor: 23.059

2.  Guidelines on the management of ascites in cirrhosis.

Authors:  K P Moore; G P Aithal
Journal:  Gut       Date:  2006-10       Impact factor: 23.059

Review 3.  [Hepatorenal syndrome].

Authors:  I Kürer; A Sommerer; G Puhl; U Kaisers; W Boemke
Journal:  Anaesthesist       Date:  2006-01       Impact factor: 1.041

4.  Clinical and hormonal conditions associated with sodium retention in cirrhotic patients with ascites. Evaluation by univariate and multivariate analyses.

Authors:  S Gentile; M Angelico; M G Chiappini; G Peruzzi; S Vulterini
Journal:  Dig Dis Sci       Date:  1987-06       Impact factor: 3.199

5.  Jejunal permeability to water and electrolytes in patients with chronic intrahepatic hypertension: evidence for a role of aldosterone.

Authors:  B Duclos; P Bories; J C Mathieu-Daude; H Michel
Journal:  Gut       Date:  1991-06       Impact factor: 23.059

6.  Renal function in fulminant hepatic failure: haemodynamics and renal prostaglandins.

Authors:  F Guarner; R D Hughes; A E Gimson; R Williams
Journal:  Gut       Date:  1987-12       Impact factor: 23.059

Review 7.  Reappraising the spectrum of AKI and hepatorenal syndrome in patients with cirrhosis.

Authors:  Juan Carlos Q Velez; George Therapondos; Luis A Juncos
Journal:  Nat Rev Nephrol       Date:  2019-11-13       Impact factor: 28.314

8.  Renal function impairment induced by change in posture in patients with cirrhosis and ascites.

Authors:  M Bernardi; C Santini; F Trevisani; M Baraldini; A Ligabue; G Gasbarrini
Journal:  Gut       Date:  1985-06       Impact factor: 23.059

9.  Angiotensin receptor blockers are superior to angiotensin-converting enzyme inhibitors in the suppression of hepatic fibrosis in a bile duct-ligated rat model.

Authors:  Moon Young Kim; Soon Koo Baik; Dong Hun Park; Yoon Ok Jang; Ki Tae Suk; Chang Jin Yea; Il Young Lee; Jae Woo Kim; Hyun Soo Kim; Sang Ok Kwon; Mi Yun Cho; Sang Baik Ko; Sei Jin Chang; Soon Ho Um; Kwang-Hyub Han
Journal:  J Gastroenterol       Date:  2008-11-18       Impact factor: 7.527

10.  Genetic linkage maps of Eucalyptus grandis and Eucalyptus urophylla using a pseudo-testcross: mapping strategy and RAPD markers.

Authors:  D Grattapaglia; R Sederoff
Journal:  Genetics       Date:  1994-08       Impact factor: 4.562

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.